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ABSTRACT
Pulmonary artery hypertension is defined as an increased in pulmonary artery pressure 
exceeding 25 mmHg with normal pulmonary wedge pressure. The pathogenesis of pulmonary 
artery hypertension involves interaction among vascular, cellular and biomarker components 
in the pulmonary tissue; with eventual result is elevated pulmonary artery pressure. Vascular 
components are remodeling of intimal, medial and adventitial layers. Cellular components are 
played by apoptosis-resistant endothelial cells, proliferative-prone pulmonary artery smooth 
muscle cells, fibroblasts and inflammatory cells. The functional biomarkers are produced and 
mediated by these cellular changes, mainly endothelin-1, thromboxane, serotonin, nitric oxide, 
and prostacyclin. The pulmonary vascular remodeling in pulmonary artery hypertension are 
diverse and may present in various severity based on underlying etiology. Understanding the 
shared pathogenesis in pulmonary artery hypertension is of paramount importance in order to 
improve the disease management and treatment approach.
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INTISARI
Hipertensi arteri paru didefinisikan sebagai peningkatan tekanan arteri paru melebihi 25 
mmHg dengan tekanan baji paru yang normal. Patogenesis hipertensi arteri paru melibatkan 
interaksi diantara komponen vaskular, sel dan biomarka dalam jaringan paru; dengan hasil akhir 
peningkatan tekanan arteri paru. Komponen vaskular berupa remodeling lapisan intima, media 
dan adventitia. Komponen sel dimainkan oleh sel endotel yang tahan-apoptosis, sel otot polos 
arteri paru yang mudah proliferasi, fibroblas dan sel radang. Biomarka fungsional diproduksi dan 
diperantarai oleh perubahan-perubahan sel ini terutama endothelin-1, thromboksan, serotonin, 
nitric oxide, dan prostasiklin. Remodeling vaskular paru pada hipertensi arteri paru beraneka dan 
bisa muncul dalam berbagai derajat keparahan tergantung etiologi yang mendasari. Memahami 
patogenesis bersama pada hipertensi arteri paru merupakan hal yang sangat penting untuk 
memperbaiki manajemen penyakit dan pendekatan terapi. 
INTRODUCTION
Pulmonary artery hypertension is considered 
to be a progressive disease. It is defined as an 
increased in pulmonary artery pressure exceeding 
25 mmHg with normal pulmonary wedge pressure.1 
Pathogenesis of pulmonary artery hypertension 
is hallmarked by pulmonary vascular remodeling. 
Pulmonary vascular remodeling involves the 
cellular and molecular modification of the pulmonary 
vasculature, both reversible or irreversible. All 
three layers of pulmonary vasculatures, i.e. 
adventitial, medial and intimal layers, undergo 
physiological and morphological changes, both 
consecutively and concomitantly. Thickening of 
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all layers due to cellular growth and proliferation 
and pathological accumulation of certain cell types 
and products, such as cytokines, chemokines 
and matrix componenst, are interplayed in the 
microenvironment of pulmonary vasculature.2  
In addition to structural remodeling from its 
native vascular cells, perivascular microenvironment 
played by surrounding cellular components, both 
from resident cells and migrated cells from remote 
origin, is supportive in the pathogenesis of pulmonary 
artery hypertension.3 These components release 
cellular products or biomarkers, in response to 
various stimuli. Release of functional biomarkers, 
mostly those related to maintenance of pulmonary 
vascular vasoconstriction and vasodilatation, 
is predominant. Inflammatory cytokines and 
chemokines, produced by inflammatory cells, are 
redundantly increased during development toward 
pulmonary hypertension.4 The aim of this review 
is to discuss the current shared pathogenesis 
prevailing in pulmonary artery hypertension.  
DISCUSSION
Pulmonary Vascular Structural Remodeling
Increased pulmonary artery pressure is 
mainly due to increased resistance in pulmonary 
vasculature. In normal condition, pulmonary 
circulation is a high flow and low pressure 
circulation. The pulmonary arterioles are the 
main regulator of pulmonary vascular resistance 
in a whole. These resistance vessels alter their 
anatomy and perivascular microenvironment in 
response to increased intraluminal shear stress.5 
This pathological shear stress triggers abnormal 
pulmonary vascular tone, which is is mediated by 
modulation of endothelial-derived relaxing factor 
and contracting factors.2 Normally, pulmonary 
arterioles consist of single layer endothelial cell 
and lined by single non-continuous smooth muscle 
cells. In remodeling, these smooth muscle cells 
are hypertrophied and extend into distal part of 
arterioles, dubbed distal muscularization.2 Whole 
layers of pulmonary artery, i.e intimal, medial and 
adventitial layers, undergo remodeling under 
persistent pathological shear stress.
Intimal layer of pulmonary artery is lined 
by single layer endothelial cells and thin basal 
membrane. The thickening of intimal layer is 
occurred in pulmonary artery hypertension due 
to the deposition of matrix protein and collagen. 
The matrix protein and collagen are generated by 
fibroblasts and myofibroblasts, which are recruited 
in subintimal area. They form regular and concentric 
or irregular and eccentric thickening of the subintimal 
and intimal layers.6 The thickening of this intimal 
layer is called neointima. This neointima cause 
occlusive or almost occlusive of luminal artery. The 
histopathology examination of neointimal shows 
concentric laminar and/or nonlaminar fibrosis.6 The 
Figure 1. The pulmonary vascular remodeling 
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disorganized proliferation of endothelial cells leads 
to formation of the plexiform lesion, an important 
sign of severe pulmonary hypertension.2 The cells 
in the plexiform lesion consist of angiogenesis-
expressing endothelial cells and supported 
by a stroma containing matrix proteins and 
myofibroblasts.7 This lesion will transform into an 
intraluminal concentric obstruction composed of 
endothelial cells, recruited myofibroblasts, fibrous 
scar and foci of thrombosis.6
Medial layer of pulmonary artery mostly 
consists of smooth muscle cells. In the early 
changes during pathophysiology of pulmonary 
artery hypertension, vascular smooth muscle 
cells increase its size (hypertrophy) and change 
into proliferative state (hyperplasia). The 
hypertrophied smooth muscle cells usually in the 
proximal branch of pulmonary artery, whereas the 
hyperplasia occurs in the more distal vessel. The 
phenotype of vascular smooth muscle is altered 
into hyperproliferative smooth muscle cells which 
release matrix protein and collagen.7 Increased 
medial thickness in pulmonary vasculature is due 
to smooth muscle cell hypertrophy and hyperplasia, 
matrix protein and collagen accumulation, and 
myofibroblast differentiation from fibroblast.2 Not 
only anatomical changes, the functional changes 
in remodeled medial layers also contribute to 
pulmonary artery hypertension.4
The adventitia layer of pulmonary artery 
is compiled by connective tissues that surround 
the airways and pulmonary arteries. It contains 
lymphatic vessels and vasa vasorum, therefore 
a channel for inflammatory cells and rich source 
of cytokines/chemokines.4 The adventitial 
fibroblast is activated under hypoxia, strenuous 
shear-stress or cytokine/chemokine stimuli.3 
This activation produces matrix protein and 
promotes thickening of adventitial layer. It 
also produces pro-inflammatory cytokines/
chemokines and recruites macrophages and 
leukocytes which induce perpetual inflammatory 
state and neovascularisation which supply 
inflammatory components in the more inner 
vascular layers, i.e. medial and intimal layers.3 In 
addition to inflammation conduit, adventitial layer 
also an entrance for endothelial progenitor cells 
and mesenchymal and bone marrow–derived 
stem cells in which involve in the pathogenesis 
of pulmonary artery hypertension.8,9 Figure 1 
dopicted pulmonary vascular remodeling.
Cellular Activation and Modification
In  addi t ion to  vascular  s t ructura l 
remodeling in the pathogenesis of pulmonary 
hypertension, cellular activation and subsequent 
modification are also an integral part of the 
pathogenesis. The cellular components are 
Figure 2. Cellular components of pulmonary vascular remodeling
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played by apoptosis-resistant and angiogenesis-
expressing endothelial cells, proliferative-prone 
pulmonary smooth muscle cells, myofibroblasts 
and modified inflammatory cells. The source 
of these cells are resident endothelial, smooth 
muscle, and fibroblast/ myofibroblast progenitors 
as well as derived from circulating progenitor 
cells which are recruited by chemokine signaling 
in pulmonary microenvironment.9  
Endothelial cells in the plexiform lesion 
excessively express angiogenic factor, vascular 
endothelial growth factor (VEGF). It suggests 
that certain endothelial cells generate self growth 
signals to which they are reactive. The net 
effect is the growth-responsive and apoptosis-
resistant cells resembling neoplastic phenotype.10 
Resident fibroblasts, mostly reside in adventitial 
layer, are activated and differentiated into 
myofibrolasts which are capable of producing 
matrix protein and collagen, gaining mobility to 
inner vascular layer and recruiting inflammatory 
cells.3 The inflammatory cells, which consist of 
macrophages, monocytes, T lymphocytes and 
dendritic cells, are abundant in perivascular 
layer and scattered in adventitial layers.5 Figure 
2 dopicted cellular components in pulmonary 
vascular remodeling.
Biomarker Release and Alteration
The role of biomarkers in the pathogenesis 
of pulmonary hypertension has been widely 
investigated. The functional biomarkers are 
produced during pulmonary vascular remodeling 
and cellular changes, mainly endothelin-1, 
thromboxane, serotonin, nitric oxide, prostacyclin 
and adrenomedulin. Endothelin-1 is a potent 
vasoconstrictor. It stimulates smooth muscle cell 
proliferation, nitric oxide and prostacyclin release 
and fibroblast activation.8 Vasoconstriction is also 
mediated by thromboxane which is overproduced 
in pulmonary vascular remodeling. Because 
of the stimuli of chronic hypoxia, pathologic 
shear stress and various injuries, endothelial 
cells in the pulmonary circulation generate 
extensively vasoconstrictor and pro-proliferative 
mediators, mainly endothelin-1, angiotensin-II and 
thromboxane A2.11 On the other hand, they produce 
less vasodilator and anti-proliferative mediators, 
i.e. nitric oxide and prostacyclin. This imbalance 
state may serve to maintain vessel wall tension and 
favors to the remodeled pulmonary vascular under 
hypertensive state. The abnormal endothelial cells 
are a principal initiator of pathologic pulmonary 
vascular remodeling, through released and altered 
Figure 3. Biomarkers involve in pulmonary vascular remodeling
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biomarker functionality.11  
Inflammation is a stimuli of pulmonary 
vascular remodeling. Cytokines and chemokines 
are contributors for developing perivascular 
inflammation. Interleukin-1 (IL-1), IL-6, IL-8, IL-
20 and IL-12 are major cytokines correlate with 
severity of pulmonary hypertension.4 Elevated 
plasma level of tumor necrosis factor α is also 
prevailed in pulmonary artery hypertension.12 
Increased chemokines level is identified such 
as fractalkine, monocyte chemotactic protein 
and CCL5 (RANTES), which contribute toward 
developing pulmonary artery hypertension.12 
Platelet and plasma level of serotonin are 
increased in pulmonary hypertension. Increased 
bioavailability of serotonin, a vasocontrictor and 
profibrotic biomarker, due to increased serotonin 
release from platelets and endothelial cells 
is prevailing in pulmonary hypertension.8 The 
effect of increased serotonin level in pulmonary 
circulation is hyperplasia and hypertrophy 
of pulmonary artery smooth muscle cells.11 
Serotonin transporter (SERT) overexpressed 
by pulmonary artery smooth muscle cells is 
responsible for the upregulated mitogenic activity 
of serotonin by these cells.8 SERT increased 
expression enhances serotonin transport into 
pulmonary smooth muscle cells and induces 
medial thickening and distal muscularisation.13 
In patients with idiopathic pulmonary artery 
hypertension, the expression of SERT is 
increased which is associated with susceptibility 
to plasma serotonin mitogenic activity.11 Figure 
3 depicted the associated biomarkers and 
pulmonary vascular remodeling.
CONCLUSION
Pathophysiology of pulmonary artery 
hypertension involves complex mechanisms 
consisting delicate interaction among pulmonary 
vascular structures, cellular modification and 
biomarker alteration. Understanding each 
component of mechanisms is of paramount 
importance in order to improve the disease 
management and treatment approach.
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